A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2017
At a glance
- Drugs MEDI 0382 (Primary) ; Liraglutide; Metformin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 08 Sep 2017 Planned End Date changed from 29 Apr 2020 to 27 Apr 2020.
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.
- 03 Aug 2017 New trial record